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ABSTRACT 
Objective: Simple, accurate and precise spectrophotometric methods have been developed for the determination of two antihistaminic drugs 
(desloratadine (DES) and ebastine (EBS)) in pure forms and pharmaceutical formulations.  
Methods: The proposed methods were based on the charge transfer complexation reaction of both drugs as ‘n’ electron donor with chloranilic acid 
(p-CLA) or 2, 3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) as π acceptors to give highly coloured complex species. The coloured products were 
quantitated spectrophotometrically at 459 and 460 nm using DDQ and at 532 and 533 nm using p-CLA for DES and EBS, respectively. Optimization 
of the different experimental conditions were studied.  
Results: Beer’s law was obeyed in the concentration ranges of 5.0-120 and 10-180 µg mL
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 with good correlation coefficients were ≥ 0.9995 and 
0.9992 and a relative standard deviation (R.S.D.) of ≤ 0.98 and 1.24% using DDQ and p-CLA methods, respectively. The molar absorptivity, Sandell's 
sensitivity, detection and quantification limits were also calculated. The developed methods were successfully applied for determination of the 
studied drugs in pharmaceutical formulations with good accuracy and precision and without interferences from common additives by applying the 
standard addition technique.  
Conclusion: The developed methods have been validated statistically for their accuracy, precision, sensitivity, selectivity, robustness and 




[5,6]cyclohepta [1,2b]pyridin-11-ylidene)-1-piperidine, DES is the 
descarboethoxy form of loratadine). An orally active major 
metabolite of the nonsedating antihistamine loratadine, is a 
selective, potent, peripheral H1 receptor antagonist [1]. Ebastine 
(EBS), 4-(4-benzhydryloxy-1-piperidyl)-1- (4-tert-butyl phenyl) 
butan-1-one. EBS belongs to the class of second generation 
antihistamines used for the treatment of allergic rhinitis and chronic 
idiopathic urticaria. This drug is official in British pharmacopoeia. 
Official method uses non-aqueous titrations for assay of this drug [1, 2]. 
The chemical structures of the studied drugs are shown in (Fig. 1). 
 
Fig. 1: The chemical structure of the studied antihistaminic 
drugs 
 
Several analytical methods have been reported for the 
determination of DES in biological and pharmaceutical samples and 
applied in pharmacokinetic studies. These methods include gas 
chromatography with nitrogen phosphorous detection [3], liquid 
chromatography with fluorescence detection [4, 5], ultraviolet 
detection [6-11] or mass spectrometric detection [12-14], capillary 
isotachophoresis [15], stability-indicating UPLC method [16], 
Spectrofluorimetric methods [8, 17] and spectrophotometric 
methods [8, 18-27]. Comparison between the reported 
spectrophotometric methods for determination of DES was showed 
in Table 1. Literature survey revealed that determination of EBS has 
been reported by chromatographic methods [28-37], voltammetry 
[38], spectrofluorimetry [39-41] and spectrophotometry [42-49].  
The molecular interactions between electron donors and acceptors 
are generally associated with the formation of intensely colored 
charge transfer complexes, which absorb radiation in the visible 
region [50]. A variety of electron donating compounds have been 
reported to yield charge-transfer complexes with various π-
acceptors [51-55]. The aim of the present study was directed to 
investigate simple, direct, normal cost and precise 
spectrophotometric methods for simultaneous determination of DES 
and EBS as good n-electron donors via charge transfer complexation 
with π –acceptors; chloranilic acid (p-CLA) and 2, 3-Dichloro-5,6-
dicyano-p-benzoquinone (DDQ) as chromogenic reagents in pure 
forms and dosage forms. The reaction conditions of the methods 
have been established. In addition, the molar ratio of reactants was 
determined. No interference was observed in the assay of the 
studied drugs from common excipients in levels found in 
pharmaceutical formulations. These methods are validated by the 
statistical data. 
MATERIALS AND METHODS 
Apparatus 
All absorption spectra was made using double beam Unikon 930 
spectrophotometer (Kontron Instruments, Munchen, Germany) with 
a scanning speed of 200 nm/min and a band width of 2.0 nm, 
equipped with 10 mm matched quartz cells. 
Materials and Reagents 
All chemicals and reagents used were of analytical or 
pharmaceutical grade and all solutions were prepared fresh daily.  
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Materials  
Pharmaceutical grade desloratadine (DES) was kindly supplied from 
Delta Pharma, Egypt. Aerius tablets labeled to contain (5.0 mg 
DES/tablet) was kindly supplied by SPIMACO, Al-Qassim 
Pharmaceutical Plant, Saudi Arabia, under authority of (Schering-
Plough Cooperation/USA). Desa tablets labeled to contain (5.0 mg 
DES /tablet) was kindly supplied by Delta Pharma, Egypt. 
Pharmaceutical grade ebastine (EBS) was kindly provided by Meivo 
Pharmaceutical Company, Cairo, Egypt. Bastab® tablets, labeled to 
contain (20 mg EBS/tablet) was kindly provided by Meivo 
Pharmaceutical Company, Cairo, Egypt. Ebastel® tablets, labeled to 
contain (10 mg EBS/tablet) was kindly provided by Global Napi 
Pharmaceuticals, Cairo, Egypt. 
Standard drugs solutions  
A stock standard solutions (500 μg mL-1) of DES and EBS were 
prepared by dissolving an exact weight (50 mg) of pure drugs in 5.0 
mL methanol and the volume was diluted to the mark in a 100 mL 
calibrated flask with acetonitrile. A stock solutions of DES or EBS 
(100 µg mL-1) and (5.0 x 10-3 mol L-1
Reagents  
) were prepared from suitable 
dilution of the stock standard solution. The stock solutions of drug 
are stable for a period of 3.0 days when kept in the refrigerator. 
Chloranilic acid (p-CLA), (Fluka, Switzerland) and 2, 3-Dichloro-5,6-
dicyano-p-benzoquinone (DDQ), (Merck-Schuchardt, Munich, 
Germany). Standard solutions (1.0 x 10-3 mol L-1
General Procedures 
) were freshly 
prepared in acetonitrile. The solutions were stable for at least one 
week at 4 ºC.  
Using DDQ 
Into 10- mL volumetric flasks (0.1-1.6 mL) and (0.2- 2.4 mL) of (500 
μg mL-1) DES and EBS solutions in acetonitrile, respectively were 
transferred and 2.0 mL of DDQ (1.0 x 10-3 mol L-1
Reagent 
) solution was 
added. The mixture was mixed and allowed to stand for 10 min at 60 
± 5°C for both drugs. The volume was made up to 10 mL with 
acetonitrile and the absorbance was measured at 459 and 460 nm 
for DES and EBS, respectively against a reagent blank prepared and 
treated similarly. 
 
Table 1: Comparison between the reported spectrophotometric methods for determination of DES 















UV-spectrophotometry 282.5 16-24 -- -- [19] 
UV-spectrophotometry 242 2.0-10 -- 0.11 [20] 
Eosin 549 0.31–2.81 -- -- [21] 
2,4-dichloro-6-nitrophenol (DCNP) 402 3.11-93.35 6.14x10 2.132 5 [22] 
 2,4-dinitrophenol (DNP) 426 3.11-62.17 13.72x10 1.884 5 
Picric acid (PA) 352 3.11-43.44 17.08 x10 0.559 5 
7,7,8,8-tetracyanoquinodimethane (TCNQ) 843 1.5–13 2.2968x10 0.35 4 [23] 
4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) 485 0.5-6 -- 0.112 [8] 
2,4-dinitrofluorobenzene (DNFB) 375 1.0-10 -- 0.172 
Thiocyanate cobalt 614 0.5-3.0 9.2 x10  4 [24] 
Alizarin  528 1.0-16 1.6078 x10 0.21 4 [25] 
Alizarin red S  505 0.5-12 2.1836 x10 0.08 4 
Quinalizarin  560 2.0-20 1.5213 x10 0.40 4 
 
Using p-CLA 
Into 10-mL calibrated flasks (0.2-2.8 mL) and (0.2-3.6 mL) of (500 
μg mL-1) DES and EBS solutions in acetonitrile, respectively were 
placed and 2.0 mL of p-CLA (1.0 x 10-3 mol L-1) solution was added. 
The reaction mixture was mixed and allowed to stand for 10 min at 
60 ± 5°C for both drugs. The volume was made up to 10 mL with 
acetonitrile and the absorbance was measured at 532 and 533 nm 
for DES and EBS, respectively against a reagent blank prepared and 
treated similarly. 
Procedure for pharmaceutical formulations  
The contents of twenty DSL or EBS tablets were crushed, finely 
powdered, weight out and the average weight of one tablet was 
determined. An accurate weight equivalent to 50 mg drug was 
transferred into a 100-mL calibrated flask, dissolved in least volume 
of methanol with shaking for 5.0 min and filtered through a sintered 
glass crucible (G4) to remove excipient in the powdered tablets. The 
filtrate was diluted to 100 mL with acetonitrile in a 100 mL 
measuring flask to give 500 μg mL-1 
The stoichiometric ratios of the charge transfer complexes formed 
between the drugs under investigation and the reagents were 
determined by applying the continuous variation attributable to 
Job's, 1971 [56] at the wavelengths of maximum absorbance. 
Equimolar solutions was employed: a 1.0 x 10
stock solution of drug. Aliquot of 
the cited solutions was taken and analyzed as described under the 
above recommended procedures for construction of calibration 
curves. For the proposed methods, the content of tablets was 
calculated using the corresponding regression equation of the 
appropriate calibration graph. The method of standard addition was 
used for the accurate determination of drugs contents. 
Stoichiometric Relationship 
-3 mol L-1 standard 
solutions of drugs and 1.0 x 10-3 mol L-1 solutions of reagents (DDQ 
or p-CLA) were used. A series of solutions was prepared in which the 
total volume of drug and reagent was kept constant at 2.0 mL. The 
drugs and reagents were mixed in various complementary 
proportions (0:2, 0.2:1.8, 0.4:1.6,………..2:0, inclusive) and completed 
to volume in a 10-mL calibrated flask with acetonitrile following the 
above mentioned procedure. The absorbance of the resultant charge 
transfer complex was measured at optimum wavelengths after 
treating each reagent at best time and temperature against a reagent 
blank following the above mentioned procedures. 
RESULTS 
Absorption spectra 
In the present investigation, we investigate the development of 
simple, rapid, accurate and reproducible spectrophotometric 
methods for determination of DES and EBS in bulk powders and 
pharmaceutical formulations based on the formation of charge-transfer 
complex of both drugs as electron-donor with selected π-acceptors (p-
CLA and DDQ) in acetonitrile. They produce a new band of absorption 
intensity at 459 and 460 nm using DDQ method and at 532 and 533 nm 
using p-CLA method for DES and EBS, respectively (Figures 2 and 3).  
Optimization of Reaction Conditions 
The influence of different parameters on the colour development 
was studied to determine optimum conditions for the assay 
procedures. 
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Effect of solvents 
Different solvents such as acetone, methanol, ethanol, 
dichloromethane, 1,2-dichloroethane, acetonitrile and chloroform 
were examined. Acetonitrile was found to be the best solvent for all 
the reagents, because it has a high relative permittivity which 
ensures the maximum yield of DDQ.- and p-CLA.- species. The other 
solvents, chloroform, acetone, dichloromethane and 1,2-
dichloroethane are possible substitutes. The formation of DDQ.- and 
p-CLA.- radicals was possible in methanol or ethanol, however, the 
colour intensity was lower than in acetonitrile. 
 
Fig. 2: Absorption spectra of the reaction product of 80 μg mL−1 
DES and 120 μg mL−1 EBS with (1.0 x 10-3 mol L-1) DDQ in 
acetonitrile, respectively against DDQ reagent blank solution. 
 
Fig. 3: Absorption spectra of the reaction product of 140 μg mL−1 
DES and 180 μg mL−1 EBS with (1.0 x 10-3 mol L-1) p-CLA in 
acetonitrile, respectively against p-CLA reagent blank solution. 
 
Effect of reagent concentration 
The optimum concentration that give maximum colour formation 
using 2.0 mL of (1.0 x 10-3 mol L-1
The optimum reaction time was determined by following the colour 
intensity at ambient temperature (25 ±2 °C). Complete colour 
development was attained after 10 min on raising the temperature 
on a water-bath to 60 ± 5 °C using both DDQ and p-CLA methods. 
The colour remained stable for at least 4.0 and 6.0 h for DDQ and p-
CLA reagent complexes, respectively. 
) DDQ or p-CLA solutions was 
found to be sufficient for the production of maximum and 
reproducible colour intensity in acetonitrile. Higher concentrations 
of the reagent did not affect the colour intensity (Figure 4).  
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) DDQ reagent 
concentration on the absorbance of charge transfer complexes 
formed with DES and EBS. 
 
Stoichiometry of the reaction 
The stoichiometric ratio of the reactants (drug: reagent) was 
determined by Job’s method [56] of continuous variation for the 
reaction between drugs and DDQ or p-CLA reagents, which shows that 
the interaction occurs between an equimolar solution of the drug and 
the reagent. The result indicated that the charge transfer complex was 
formed in the ratio of 1:1 (Figure 5). On the basis of the literature data 
and our experimental results, tentative reaction mechanisms for EBS-
DDQ complex is proposed and given in Scheme 1. 
 
Fig. 5: Continuous variation plots for the reaction of DES and 
EBS with DDQ. λmax= 459 and 460 nm, respectively. Total molar 
concentration = 1.0 x 10-4 mol L-1. 
 
Method validation 
Validation of the described methods for assay of bulk amisulpride 
was examined via linearity, sensitivity, precision, accuracy, 
repeatability, reproducibility, selectivity, and robustness according 
to ICH guidelines [57]. 
Linearity and sensitivity 
Under the optimum conditions a linear correlation was found 
between absorbance at λmax and concentration of drugs in the ranges 
of 5.0-120 μg mL-1 and 10-180 μg mL-1
(Where A = absorbance, a = intercept, b = slope and C = 
concentration in μg mL
 using DDQ and p-CLA 
methods, respectively. The calibration graph is described by the 
regression equation:  
A = a + b C (1) 
-1) obtained by the method of least squares 
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[58]. Correlation coefficient, intercept and slope for the calibration 
data are summarized in Table 2. For accurate determination, 
Ringbom concentration ranges [59] were calculated by plotting log 










































 against transmittance % from 
which the linear portion of the curve gives accurate range of 
microdetermination of drugs and represented in Table 2. Sensitivity 
parameters such as apparent molar absorptivity (ε) and Sandell’s 
sensitivity (SS) values, the limits of detection and quantification 
were calculated as per the current ICH guidelines (ICH) [57], are 
illustrated in Table 2. 
 
Scheme 1: Proposed reaction pathway for the formation of 
charge transfer complex between EBS and DDQ. 
 
The high molar absorptivity and lower Sandell’s sensitivity values 
reflect the good and high sensitivity of the proposed methods. The 
validity of the proposed methods was evaluated by statistical 
analysis [60] between the results achieved from the proposed 
methods and that of the reported methods [25, 39]. Regarding the 
calculated Student’s t-test and variance ratio F-test (Table 2), there 
is no significant difference between the proposed and reported 
methods regarding accuracy and precision. 
The limit of detection (LOD) is defined as the minimum level at 
which the analyte can be reliably detected for the drug was 
calculated using the following equation [57, 60] and listed in Table 2:  
LOD = 3s / k 
where s is the standard deviation of replicate determination values 
under the same conditions as for the sample analysis in the absence 
of the analyte and k is the slope of the calibration graph. In 
accordance with the formula, the limits of detection were found to 
be 1.38 and 2.85 µg mL−1
The limits of quantification, LOQ, is defined as the lowest 
concentration that can be measured with acceptable accuracy and 
precision[57, 60], 
 using DDQ and 2.85 and 2.46 using p-CLA 
for DES and EBS, respectively.  
LOQ = 10 s / k 
According to this equation, the limit of quantification was found to 
be 4.60 and 9.50 µg mL−1
Accuracy and precision 
The accuracy and precision of the proposed methods (within-day 
and between-days) were evaluated by performing six replicate 
analyses on pure drug solution at three different concentration 
levels (within the working range). Percentage relative standard 
deviation (RSD%) as precision and percentage relative error (RE%) 
as accuracy of the proposed spectrophotometric methods were 
calculated. The relative standard deviation (RSD) values were ≤ 
1.20% in all cases, indicating good repeatability of the suggested 
methods. This level of precision of the proposed methods was 
adequate for the quality control analysis of the studied drugs.  
The percentage relative error (RE %) calculated using the following 
equation:  
 using DDQ and 9.50 and 8.20 using p-CLA 






RE % is an indicator of accuracy in the range (-0.9-0.3) also 
indicating high accuracy and repeatability of the methods. The intra-
day and inter-day precision and accuracy results show that the proposed 
methods have good repeatability and reproducibility reflecting the 
usefulness of the methods in routine analysis (Table 3). 
 
Table 2: Analytical and regression parameters of proposed spectrophotometric methods for determination of DES and EBS. 
Parameters DDQ p-CLA 
DES EBS DES EBS 
Wavelengths λR maxR (nm) 459 460 532 533 
Beer’s law limits (µg mLP−1 P) 5.0-80 10-120 10-140 10-180 
Ringbom optimum concentration range  
(µg mLP−1 P) 
10-60 20-100 20-120 20-160 
Molar absorptivity ε, (L/mol P-1 P cm P-1 P) x 10 P3 1.5147 2.7373 1.1391 1.4117 
SandellP,Ps sensitivity (ng cm P-2 P) 205 172 273 333 
Regression equation Pa P     
Slope (b) 0.0045 0.0064 0.0038 0.0028 
Intercept (a) 0.0038 - 0.0041 -0.0033 0.0028 
Correlation coefficient (r) 0.9993 0.9992 0.9995 0.9997 
Mean ± SD 99.70 ± 1.24 99.90 ± 0.62 99.80 ± 0.98 99.85 ± 0.70 
Relative standard deviation, RSD% 1.24 0.62 0.98 0.70 
Relative error, RE% 1.30 0.65 1.03 0.73 
LOD, (µg mLP−1 P) P b 1.38 2.85 2.85 2.46 
LOQ, (µg mLP−1 P) P b 4.60 9.50 9.50 8.20 
Calculated t-value P c 0.28 0.52 0.16 0.62  
Calculated F-value Pc 1.20 1.42 1.33 1.81 
P
a
P A = a + bC, where C is the concentration in µg mLP−1 P, A is the absorbance units, a is the intercept, b is the slope. PbP LOD, limit of detection; LOQ, limit of 
quantification; ε, molar absorptivity. Pc P The theoretical values of t and F are 2.57 and 5.05, respectively at confidence limit at 95% confidence level 
and five degrees of freedom (p= 0.05). 
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Table 3: Evaluation of inter-day and intra-day precision and accuracy for the determination of DES and EBS using the proposed DDQ method 




















limit  a b 
  DDQ method 
DES 20 99.60 0.40 -0.40 19.92±0.08 99.40 0.45 -0.60 19.88 ± 0.09 
40 99.10 0.60 -0.90 39.64±0.25 99.20 0.74 -0.80 39.68 ± 0.31 
80 99.80 0.90 -0.20 79.84±0.75 99.50 0.96 -0.50 79.60 ± 0.80 
EBS 20 99.50 0.37 -0.50 19.90±0.08 99.60 0.52 -0.40 19.92 ± 0.10 
60 99.70 0.73 -0.30 59.82±0.46 99.10 0.85 -0.90 59.46 ± 0.53 
100 99.20 1.10 -0.80 99.20±1.15 100.20 1.20 0.20 100.20 ± 1.26 
  p-CLA method 
DES 20 99.80 0.38 -0.20 19.96±0.08 99.30 0.47 -0.70 19.86±0.10 
80 99.40 0.72 -0.60 79.52±0.60 99.50 0.70 -0.50 79.60±0.58 
140 100.20 1.16 0.20 140.28±1.71 99.70 0.98 -0.30 139.58±1.44 
EBS 30 100.30 0.50 0.30 30.09 ± 0.09 99.50 0.30 -0.50 29.85 ± 0.09 
90 99.50 0.86 -0.50 89.55 ± 0.81 100.20 0.56 0.20 90.18 ± 0.53 
150 99.70 1.05 -0.30 149.55 ± 1.65 99.60 0.86 -0.40 149.40 ± 1.35 
P
a
P Mean of six determination, RSD%, percentage relative standard deviation; RE%, percentage relative error, PbP Mean ± standard error. 
 
Robustness and ruggedness 
The robustness of the methods was evaluated by making small 
incremental changes in the volume of reagent (± 0.2 mL) and time 
(±1.0 min), and the effect of the changes were studied on the 
absorbance of the charge transfer complex. The changes had 
negligible influence on the results as revealed by small intermediate 
precision values expressed as %RSD (≤ 3.0%). 
 
 Method ruggedness was demonstrated having the analysis done 
by three analysts, and also by a single analyst performing 
analysis using three different spectrophotometer instruments in 
the same laboratory. Intermediate precision values (%RSD) in 
both instances were (≤ 2.0%) indicating acceptable ruggedness 
(Table 4). 
Table 4: Method robustness and ruggedness expressed as intermediate precision (RSD, %) for EBS-acceptors charge transfer 
complex. 
Method EBS taken 
(μg mLP-1P) 
Robustness Ruggedness 
Parameters altered Inter-analysts (RSD, %) Inter-instruments (RSD, %) 
   Volume of reagent P a Reaction time Pb (n = 3) (n = 3) 
DDQ 20 1.10 1.40 1.30 1.80 
 60 1.32 1.75 1.80 2.20 
 100 1.64 1.60 2.30 2.50 
p-CLA 30 1.30 1.20 1.40 1.50 
 90 1.20 1.80 1.70 1.90 
 180 1.95 2.10 2.40 2.30 
P
a 
PThe volumes added of DDQ or p-CLA were 2.0±0.2 mL, PbP The reaction times were 10±1.0 min for p-CLA or DDQ.  








Recovery P aP (%) Added 
(μg 
mLP-1P) 





















 10 - 99.20  99.40  - 99.10  99.70  
 10 99.50  99.90  20 100.40  99.80  
 20 98.40  99.30  40 99.60  100.20  
 40 98.60  99.50  60 100.50  99.90  
 60 100.80  100.60  80 100.70  99.30  
 70 99.30  98.70  100 99.20  100.80  
Mean ±  
SD  
  99.30 
± 
0.849 







 99.92 ± 
0.703 
99.88 ± 0.61 99.95 ± 
0.509 
100.23 ±  
0.48 
V   0.72 1.04 0.41 0.865  0.494 0.372 0.259 0.23 
R.S.D%   0.843 1.02 0.64 0.93  0.703 0.61 0.509 0.48 
S.E   0.364 0.416 0.26 0.38  0.287 0.249 0.208 0.196 
T value Pb   0.59  0.18   0.07  0.89  
F-value P 
b 
  1.20  2.11   1.33  1.13  
P
a 
PAverage of six determinations.,PbP The theoretical values of t and F are 2.57 and 5.05, respectively at confidence limit at 95% confidence level and five 
degrees of freedom (p= 0.05). 
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Recovery studies    
The accuracy and validity of the proposed methods were further 
ascertained by performing recovery studies. In this study, pre-
analyzed tablets powder was spiked with pure drugs at different 
concentration levels and the total was determined by the proposed 
methods using standard addition technique.  
 
The percent recovery of pure drugs added was in the range 
98.30–100.80% with relative standard deviation of 0.509–0.94% 
(Tables 5, 6) indicating that the recovery was good and revealed 
that the co-formulated substances did not interfere in the 
determination
 






































 20 - 98.40  100.30  - 99.20  99.20  
 20 100.10  99.20  20 99.10  99.60  
 40 99.00  98.50  40 100.60  99.90  
 60 98.50  98.30  80 99.50  100.70  
 80 99.60  99.70  120 100.50  100.50  
 100 100.80  100.60  160 100.50  100.60  
Mean ±  
SD  










 99.90 ± 
0.707 




V   0.892 1.04 0.79 0.93  0.50 0.372 0.374 0.23 
R.S.D%   0.94 1.02 0.88 0.865  0.707 0.61 0.61 0.48 
S.E   0.385 0.416 0.363 0.38  0.289 0.249 0.25 0.196 
t-value P b   0.40  0.17   0.05  0.43  
F-value P 
b 
  1.17  1.09   1.34  1.62  
P
a 
PAverage of six determinations., PbP The theoretical values of t and F are 2.57 and 5.05, respectively at confidence limit at 95% confidence level and 
five degrees of freedom (p= 0.05). 
 
Interference studies 
The studied drugs were determined in the presence of possible 
excipients and additives such as lactose, microcrystalline cellulose, 
sodium starch glycolate and magnesium stearate. Under the 
experimental conditions employed, to a known amount of drugs, 
excipients in different concentrations were added and studied. 
Excipients do not interfere with the assay. In addition, recoveries 
in most cases were around 100% and the lower values of the RSD 
(≤ 2.0%) indicate the good precision of the methods. Regarding the 
interference of the excipients and additives usually presented in 
pharmaceutical formulation and interference due to the 
degradation products of drugs, the energy of the charge transfer 
(ERCTR) depends on the ionization potential (IRPR) of the donor and the 
electron affinity of the acceptor (ERAR), hence the λRmaxR values of the 
other π-donors mostly differ from that of the investigated 
compounds if they are able to form charge transfer complexes. 
Preliminary experiments showed that all additives, excipients and 
degradate products did not form charge transfer complexes with 
the studied acceptors indicating the high selectivity of the 
proposed methods and applicability to use for routine 
determination in pure and in dosage forms. 
Application of the proposed methods to the analysis of tablets 
In order to evaluate the analytical applicability of the proposed 
methods to the quantification of the studied drugs in commercial 
tablets, the results obtained by the proposed methods were 
compared with those of the reference methods [25, 39] by applying 
Student’s t-test for accuracy and F-test for precision. The results 
(Table 5, 6) show that the Student’s t- and F-values at 95% 
confidence level are less than the theoretical values, indicating that 
there is a good agreement between the results obtained by the 
proposed methods and the reference method with respect to 
accuracy and precision. 
DISCUSSION 
Chloranilic acid (p-CLA) exists in three ionic forms, the neutral 
yellow- orange HR2RA at very low pH, the dark purple HAP− P which is 
stable at pH 3.0 and a colorless A P2− P, which is stable at high pH; these 
transformations are illustrated in the following scheme: 
HR2RA HP+ P+HA P− P(violet), 
HA P− P HP+ P+A P2− P(colorless). 
Since the interaction of the studied drugs with p-CLA in acetonitrile 
forms charge transfer complex gave a violet product (p-CLA radical 
anion) which absorbing maximally at wavelength 532 and 533 nm 
for DES and EBS, respectively, it might be concluded that HA P− P was 
the form of p-CLA involved in the reaction described herein. This 
compound is considered to be an intermediate molecular association 
complex which dissociates in the corresponding radical anions in 
acetonitrile solvent. The reaction of the studied drugs with DDQ 
yields intense orange-red colored radical anion (DDQ P.− P) in 
acetonitrile, which exhibits two absorption maxima at 532 and 459 
nm for DES and at 527 and 460 nm for EBS. The 459 and 460 nm 
band for DES and EBS, respectively, having the highest absorption 
intensity were selected for construction of Beer's plot. nm The 
predominant colour with DDQ is from the reddish brown radical 
anion DDQ P.- P, which was probably formed by the dissociation of an 
original donor-acceptor (DA) complex with the studied drugs. 
The interaction of the studied drugs with selective polyhaloquinone 
and polycyanoquinone π-acceptors in non-polar solvents such as 
dichloroethane was found to produce colored charge-transfer 
complexes with low molar absorptivity values. In polar solvents such 
as acetonitrile, complete electron transfer from the studied drugs 
(D), as an electron donor, to the acceptor moiety (A) takes place with 
the formation of intensely colored radical ions with high molar 





DA complexDonor Acceptor  
The dissociation of the (D–A) complex was promoted by the high 
ionizing power of the polar solvent and the resulting peaks in the 
absorption spectra of D-acceptor reaction mixtures were similar to 
Gouda et al. 
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the maxima of the radical anions of the acceptors obtained by the 
iodide reduction method. Further support for the assignment was 
provided by the comparison of the absorption bands with those of 
the DDQ.- and p-CLA.- 
The present study described the successful evaluation of 




acceptors (DDQ and p-CLA) as analytical reagents in the 
development of simple and rapid charge transfer complexation 
spectrophotometric methods for the accurate determination of DES 
and EBS in bulk drugs and its tablets and validated as per the 
current ICH guidelines. The present spectrophotometric methods 
are characterized by simplicity since they do not involve any critical 
experimental variable and are free from tedious, time-consuming, 
extraction steps and do not need expensive sophisticated apparatus 
unlike many previous methods. The proposed methods have 
additional advantages of ease of operation and possibility of carrying 
them out with a common laboratory instrument unlike many other 
instrumental methods reported for both drugs. They are 
characterized by high selectivity and comparable sensitivity with 
respect to the existing methods. The accuracy, reproducibility, 
simplicity, and cost-effectiveness of the methods suggest their 
application in the quality control laboratories where the modern and 
expensive instruments are not available. 
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